Catabasis Pharmaceuticals,Inc. (NASDAQ:CATB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Catabasis Pharmaceuticals,Inc. (NASDAQ:CATB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On January3, 2019, the Board of Directors (the “Board”) of Catabasis Pharmaceuticals,Inc., a Delaware corporation (the “Company”) increased the size of the Board from six to seven directors and elected Gregg Lapointe as a director, effective immediately. Mr.Lapointe will serve as a ClassIII director with a term expiring at the Company’s 2021 annual meeting of the stockholders of the Company and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr.Lapointe will serve as a member of the Audit Committee of the Board.

Mr.Lapointe is the Co-Founder of Cerium Pharmaceuticals, a privately held biopharmaceutical company, and has served as its Chief Executive Officer since its founding in 2012. Prior to founding Cerium Pharmaceuticals, Mr.Lapointe worked at Sigma-Tau Pharmaceuticals,Inc., a private biopharmaceutical company, where he served as Chief Executive Officer from 2008 to 2012 and as Chief Operating Officer from 2003 to 2008. Mr.Lapointe currently serves on the Board of Directors of Cytori Therapeutics,Inc., a publicly traded specialty therapeutics company; Soligenix,Inc., a publicly traded biopharmaceutical company; and Rigel Pharmaceuticals,Inc., a publicly traded a biotechnology company. Mr.Lapointe holds a Bachelor of Commerce from Concordia University (Montreal), a graduate diploma in Accountancy from McGill University and an M.B.A. from Duke University. Mr.Lapointe is a C.P.A. in the state of Illinois. The Company believes that Mr.Lapointe is qualified to serve on the Board because of his significant experience in the areas of finance, management and specialty drug commercialization and his experience as an executive officer and board member in the pharmaceutical industry.

Mr.Lapointe will receive compensation for his service as a non-employee director in accordance with the Company’s director compensation program, including the award of one-time nonqualified stock option under the Company’s 2015 Stock Incentive Plan to purchase 2,800 shares of the Company’s common stock. The stock option was granted effective January3, 2019 and had an exercise price of $4.60 per share, which was equal to the closing price of the Company’s common stock on the Nasdaq Global Market on such grant date. The option will vest in equal annual installments over a three-year period measured from the date of grant, subject to the Mr.Lapointe’s continued service as a director. In connection with his election, Mr.Lapointe entered into an indemnification agreement with the Company in a form substantially similar to the form of indemnification agreement that the Company has entered into with its other directors. This agreement requires the Company to indemnify Mr.Lapointe for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.

About Catabasis Pharmaceuticals,Inc. (NASDAQ:CATB)

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

An ad to help with our costs